The next step in translational research: lessons learned from the first preclinical randomized controlled trial

Journal of Neurochemistry

Volumn 139, Issue , 2016, Pages 271-279

  Llovera, Gemma ^a,b   Liesz, Arthur ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

randomized controlled trial; replication crisis; stroke; study design; translational research

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; CRISIS THEORY; DATA ANALYSIS; DRUG EFFICACY; ETHICS; EXCLUSION CRITERIA; EXPERIMENTAL ANIMAL; EXPERIMENTAL BEHAVIORAL TEST; FUNDING; INCLUSION CRITERIA; LEGAL ASPECT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDIZATION; STATISTICAL ANALYSIS; STUDY DESIGN; TRANSLATIONAL RESEARCH; TYPES OF ARTICLE OR STUDY; ANIMAL; DISEASE MODEL; HUMAN; LEARNING; PRECLINICAL STUDY; PROCEDURES; REPRODUCIBILITY; STANDARDS; TRENDS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LEARNING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84960539638     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13516     Document Type: Article

References (49)

1. Bailey E. L., McCulloch J., Sudlow C. and Wardlaw J. M. (2009) Potential animal models of lacunar stroke: a systematic review. Stroke 40, e451–e458.
2. Banerjee A., Wang J., Bodhankar S., Vandenbark A. A., Murphy S. J. and Offner H. (2013) Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice. Transl. Stroke Res. 4, 554–563.
3. Bath P. M., Macleod M. R. and Green A. R. (2009) Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int. J. Stroke 4, 471–479.
4. Begley C. G. and Ellis L. M. (2012) Drug development: raise standards for preclinical cancer research. Nature 483, 531–533.
5. Butler D. (2008) Translational research: crossing the valley of death. Nature 453, 840–842.
6. Button K. S., Ioannidis J. P., Mokrysz C., Nosek B. A., Flint J., Robinson E. S. and Munafo M. R. (2013) Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 14, 365–376.
7. CAMARADES (2014) Collaborative approach to meta-analysis and review of animal data from experimental studies. www.dcn.ed.ac.uk/camarades/[ACCESSED ON 21 October 2015].
8. Carmichael S. T. (2005) Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2, 396–409.
9. Claesson M. J., Jeffery I. B., Conde S. et al. (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature 488, 178–184.
10. Collins S. M., Surette M. and Bercik P. (2012) The interplay between the intestinal microbiota and the brain. Nat. Rev. Microbiol. 10, 735–742.
11. Crossley N. A., Sena E., Goehler J., Horn J., van der Worp B., Bath P. M., Macleod M. and Dirnagl U. (2008) Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 39, 929–934.
12. Dirnagl U. (2006) Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 26, 1465–1478.
13. Dirnagl U. and Fisher M. (2012) International, multicenter randomized preclinical trials in translational stroke research: it's time to act. J. Cereb. Blood Flow Metab. 32, 933–935.
14. Dirnagl U., Hakim A., Macleod M. et al. (2013) A concerted appeal for international cooperation in preclinical stroke research. Stroke 44, 1754–1760.
15. Editorial (2013) Facilitating reproducibility. Nat. Chem. Biol. 9, 345.
16. Egger M., Davey Smith G., Schneider M. and Minder C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634.
17. Engel O., Kolodziej S., Dirnagl U. and Prinz V. (2011) Modeling stroke in mice - middle cerebral artery occlusion with the filament model. J. Vis. Exp. 47, e2423, doi:10.3791/2423.
18. Farr T. D. and Whishaw I. Q. (2002) Quantitative and qualitative impairments in skilled reaching in the mouse (Mus musculus) after a focal motor cortex stroke. Stroke 33, 1869–1875.
19. Garijo D., Kinnings S., Xie L., Xie L., Zhang Y., Bourne P. E. and Gil Y. (2013) Quantifying reproducibility in computational biology: the case of the tuberculosis drugome. PLoS ONE 8, e80278.
20. Haidich A. B. (2010) Meta-analysis in medical research. Hippokratia 14, 29–37.
21. Hetze S., Romer C., Teufelhart C., Meisel A. and Engel O. (2012) Gait analysis as a method for assessing neurological outcome in a mouse model of stroke. J. Neurosci. Methods 206, 7–14.
22. Howells D. W., Porritt M. J., Rewell S. S., O'Collins V., Sena E. S., van der Worp H. B., Traystman R. J. and Macleod M. R. (2010) Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J. Cereb. Blood Flow Metab. 30, 1412–1431.
23. Howells D. W., Sena E. S., O'Collins V. and Macleod M. R. (2012) Improving the efficiency of the development of drugs for stroke. Int. J. Stroke 7, 371–377.
24. Howells D. W., Sena E. S. and Macleod M. R. (2014) Bringing rigour to translational medicine. Nat. Rev. Neurol. 10, 37–43.
25. Hutton B., Salanti G., Chaimani A. et al. (2014) The quality of reporting methods and results in network meta-analyses: an overview of reviews and suggestions for improvement. PLoS ONE 9, e92508.
26. Ioannidis J. P. (2005) Why most published research findings are false. PLoS Med. 2, e124.
27. Ioannidis J. P., Greenland S., Hlatky M. A., Khoury M. J., Macleod M. R., Moher D., Schulz K. F. and Tibshirani R. (2014) Increasing value and reducing waste in research design, conduct, and analysis. Lancet 383, 166–175.
28. Kilkenny C., Browne W. J., Cuthill I. C., Emerson M. and Altman D. G. (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J. Pharmacol. Pharmacother. 1, 94–99.
29. Kimmelman J., Mogil J. S. and Dirnagl U. (2014) Distinguishing between exploratory and confirmatory preclinical research will improve translation. PLoS Biol. 12, e1001863.
30. Kleikers P. W., Hooijmans C., Gob E. et al. (2015) A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation. Sci. Rep. 5, 13428.
31. Lapatas V., Stefanidakis M., Jimenez R. C., Via A. and Schneider M. V. (2015) Data integration in biological research: an overview. J. Biol. Res. 22, 9.
32. Lefer D. J. and Bolli R. (2011) Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation. J. Cardiovasc. Pharmacol. Ther. 16, 332–339.
33. Llovera G., Hofmann K., Roth S. et al. (2015) Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia. Sci. Transl. Med. 7, 299ra121.
34. Longa E. Z., Weinstein P. R., Carlson S. and Cummins R. (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20, 84–91.
35. Macleod M. R., Michie S., Roberts I., Dirnagl U., Chalmers I., Ioannidis J. P., Al-Shahi Salman R., Chan A. W. and Glasziou P. (2014) Biomedical research: increasing value, reducing waste. Lancet 383, 101–104.
36. Maysami S., Wong R., Pradillo J. M. et al. (2015) A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke. J. Cereb. Blood Flow Metab. [Epub ahead of print], 0271678X15606714–10271678X15606714.
37. McNutt M. (2014) Journals unite for reproducibility. Science 346, 679.
38. Mergenthaler P. and Meisel A. (2012) Do stroke models model stroke? Dis. Model. Mech. 5, 718–725.
39. Neylon C. and Wu S. (2009) Open science: tools, approaches, and implications. Pac. Symp. Biocomput. 14, 540–544.
40. O'Collins V. E., Macleod M. R., Donnan G. A., Horky L. L., van der Worp B. H. and Howells D. W. (2006) 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467–477.
41. Perrin S. (2014) Preclinical research: make mouse studies work. Nature 507, 423–425.
42. Prinz F., Schlange T. and Asadullah K. (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discovery 10, 712.
43. Saver J. L., Jovin T. G., Smith W. S. et al. (2013) Stroke treatment academic industry roundtable: research priorities in the assessment of neurothrombectomy devices. Stroke 44, 3596–3601.
44. Schallert T., Fleming S. M., Leasure J. L., Tillerson J. L. and Bland S. T. (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777–787.
45. Tsilidis K. K., Panagiotou O. A., Sena E. S., Aretouli E., Evangelou E., Howells D. W., Al-Shahi Salman R., Macleod M. R. and Ioannidis J. P. (2013) Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol. 11, e1001609.
46. Tymianski M. (2015) Neuroprotective therapies: preclinical reproducibility is only part of the problem. Sci. Transl. Med. 7, 299 fs232.
47. Wekerle H., Berer K. and Krishnamoorthy G. (2013) Remote control-triggering of brain autoimmune disease in the gut. Curr. Opin. Immunol. 25, 683–689.
48. Wicherts J. M., Borsboom D., Kats J. and Molenaar D. (2006) The poor availability of psychological research data for reanalysis. Am. Psychol. 61, 726–728.
49. Zhou W., Liesz A., Bauer H., Sommer C., Lahrmann B., Valous N., Grabe N. and Veltkamp R. (2013) Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models. Brain Pathol. 23, 34–44.